How can breast cancer mediate triphenoxylamine resistance through autophagy?
Conditions
Interventions
Experimental group:None
Control group:None
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Signed an informed consent form; 2.The patient is a patient after radical treatment of breast cancer; 3.The patient participates in postoperative adjuvant chemotherapy; 4.No serious systemic diseases; 5.No other related treatment has been carried out, such as new adjuvant chemotherapy, etc.
Exclusion criteria
Exclusion criteria: 1.The patient refuses to sign the informed consent form; 2.The patient needs to change the postoperative adjuvant chemotherapy plan due to the condition; 3.The patient refuses postoperative adjuvant chemotherapy; 4.The termination of postoperative adjuvant chemotherapy for any reason; 5.The patient's condition changes and needs to add other treatment methods; 6.The patient requests to withdraw from the project; 7.The patient is accompanied by other serious systemic diseases after surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete various indicators of immunInvestigating the Regulatory Mechanisms of Trastuzumab Resistance in LNCRNA LINRIS/LINRIS/SAHHD/NMT3B/Beclin1 via Autophagy Activationohistochemistry using the patient's tissue samples; | — |
Countries
China
Contacts
Public ContactZhang Wei
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed